Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New epilepsy drug shows promise in reducing partial seizures

NCT ID NCT03083665

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested whether adding brivaracetam (Briviact) to existing epilepsy medications could safely reduce partial seizures in adults aged 16 to 80. About 449 participants who still had frequent seizures despite taking 1 or 2 other drugs were randomly assigned to receive brivaracetam or a placebo. The study measured seizure frequency and side effects over 12 weeks to see if the drug helps control seizures better than placebo alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brivaracetam (Briviact)
What this could lead to
If successful, brivaracetam could offer a new add-on option to help reduce partial seizures in people with epilepsy who still have seizures despite current medications.
What could go wrong
This is a completed Phase 3 trial, so results are available but may show only modest benefit over placebo. Side effects and individual responses vary, and it is an add-on therapy, not a standalone cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

449 people

The number who actually took part.

Started

Aug 2017

Finished

Jun 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects (male or female) from 16 to 80 years of age at Visit 1, both inclusive * Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method * Subjects having at least 8 partial seizures (according to the 1981 ILAE classification) during the 8-Week Baseline Period with at least 2 partial seizures during each 4-week interval of the Baseline Period * Subjects having at least 2 partial seizures whether or not secondary generalization per month during the 3 months preceding Visit 1 * Subjects uncontrolled while treated by 1 or 2 permitted concomitant antiepileptic drug \[AED\](s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED Exclusion Criteria: * Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline * Subject is currently treated with levetiracetam * Subject has taken levetiracetam within 90 days prior to Visit 1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy Partial seizures with or without secondary generalization

Contacts and locations

Locations

  • Ep0083 101

    Sapporo, Japan

  • Ep0083 102

    Kagoshima, Japan

  • Ep0083 103

    Sendai, Japan

  • Ep0083 104

    Shizuoka, Japan

  • Ep0083 105

    Nagakute, Japan

  • Ep0083 106

    Niigata, Japan

  • Ep0083 108

    Suita, Japan

  • Ep0083 109

    Yamagata, Japan

  • Ep0083 110

    Hiroshima, Japan

  • Ep0083 111

    Hamamatsu, Japan

  • Ep0083 112

    Kōshi, Japan

  • Ep0083 114

    Saitama, Japan

  • Ep0083 115

    Kokubunji, Japan

  • Ep0083 116

    Asaka, Japan

  • Ep0083 117

    Nara, Japan

  • Ep0083 118

    Nagoya, Japan

  • Ep0083 120

    Yokohama, Japan

  • Ep0083 121

    Itami, Japan

  • Ep0083 122

    Hachinohe, Japan

  • Ep0083 123

    Kodaira, Japan

  • Ep0083 124

    Kyoto, Japan

  • Ep0083 126

    Bunkyō City, Japan

  • Ep0083 127

    Bunkyō City, Japan

  • Ep0083 128

    Kurume, Japan

  • Ep0083 129

    Neyagawa, Japan

  • Ep0083 130

    Ôsaka, Japan

  • Ep0083 131

    Ōtsu, Japan

  • Ep0083 132

    Kōriyama, Japan

  • Ep0083 133

    Ushiku, Japan

  • Ep0083 136

    Nagoya, Japan

  • Ep0083 137

    Suita, Japan

  • Ep0083 138

    Tsukuba, Japan

  • Ep0083 140

    Kawasaki, Japan

  • Ep0083 141

    Higashisonogi-gun Kawatana-cho, Japan

  • Ep0083 142

    Kamakura, Japan

  • Ep0083 144

    Shinjuku-ku, Japan

  • Ep0083 146

    Chiba, Japan

  • Ep0083 147

    Kyoto, Japan

  • Ep0083 148

    Adachi-ku, Japan

  • Ep0083 150

    Yokohama, Japan

  • Ep0083 201

    Kuala Lumpur, Malaysia

  • Ep0083 202

    Perai, Malaysia

  • Ep0083 203

    Sungai Buloh, Malaysia

  • Ep0083 204

    Kuching, Malaysia

  • Ep0083 206

    Kuala Terengganu, Malaysia

  • Ep0083 207

    Kota Bharu, Malaysia

  • Ep0083 208

    Pulau Pinang, Malaysia

  • Ep0083 209

    Miri, Malaysia

  • Ep0083 301

    Manila, Philippines

  • Ep0083 302

    Manila, Philippines

  • Ep0083 303

    Cebu City, Philippines

  • Ep0083 304

    Cebu City, Philippines

  • Ep0083 306

    Davao City, Philippines

  • Ep0083 307

    Iloilo City, Philippines

  • Ep0083 309

    Quezon City, Philippines

  • Ep0083 310

    Manila, Philippines

  • Ep0083 401

    Singapore, Singapore

  • Ep0083 402

    Singapore, Singapore

  • Ep0083 501

    Tainan, Taiwan

  • Ep0083 502

    Chiayi City, Taiwan

  • Ep0083 503

    Taichung, Taiwan

  • Ep0083 504

    Taichung, Taiwan

  • Ep0083 505

    Kaohsiung City, Taiwan

  • Ep0083 601

    Khon Kaen, Thailand

  • Ep0083 602

    Bangkok, Thailand

  • Ep0083 603

    Muang, Thailand

  • Ep0083 605

    Bangkok, Thailand

  • Ep0083 606

    Bangkok, Thailand

  • Ep0083 607

    Bangkok, Thailand

  • Ep0083 608

    Muang, Thailand

  • Ep0083 609

    Bangkok, Thailand

  • Ep0083 901

    Chengdu, China

  • Ep0083 902

    Guangzhou, China

  • Ep0083 904

    Zhengzhou, China

  • Ep0083 905

    Beijing, China

  • Ep0083 906

    Beijing, China

  • Ep0083 907

    Changchun, China

  • Ep0083 908

    Lanzhou, China

  • Ep0083 909

    Guangzhou, China

  • Ep0083 910

    Shijiazhuang, China

  • Ep0083 912

    Hangzhou, China

  • Ep0083 913

    Wenzhou, China

  • Ep0083 916

    Yinchuan, China

  • Ep0083 917

    Guangzhou, China

  • Ep0083 918

    Zhanjiang, China

  • Ep0083 920

    Guangzhou, China

  • Ep0083 921

    Nanchang, China

  • Ep0083 922

    Guangzhou, China

  • Ep0083 923

    Zunyi, China

  • Ep0083 924

    Guangzhou, China

  • Ep0083 925

    Suzhou, China

  • Ep0083 926

    Pingxiang, China

  • Ep0083 927

    Xi'an, China

  • Ep0083 930

    Xinxiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.